SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Tabalumab

Cat. No.:	HY-P99220
CAS No.:	1143503-67-6
Target:	TNF Receptor
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus[1].

IC_{50} & Target

BAFF[1].

In Vitro

Tabalumab (1-100 ng/mL; 44 h) neutralizes soluble and membrane-bound BaFF both in T1165.17 cells and (1 μg/mL; 3 days) $CD19^+$ B-cells[1].

Tabalumab (50 μg/mL; 15 min) inhibits BaFF binding to BR3, TacI, and BcMa in HEK293 cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	T1165.17 cells
Concentration:	1-100 ng/mL
Incubation Time:	44 h
Result:	Neutralizeed tabalumab neutralization of soluble human, cynomolgus monkey, or rabbit BAFF with IC_{50} values of 104, 143, and 176 pM in T1165.17 cells, respectively.

Cell Viability Assay[1]

Cell Line:	$CD19^+$ B-cells
Concentration:	1 μg/mL
Incubation Time:	3 days
Result:	Demonstrated the ability to neutralize the membrane-bound form of BAFF compared with the soluble form of BAFF.

Cell Viability Assay[1]

Cell Line:	HEK293 cells (transfected with either BR3, TACI, or BCMA)

Concentration:	50 μg/mL
Incubation Time:	15 min (pre-treat)
Result:	Prevented the binding of BAFF to BR3, TACI, or BCMA on the cell surface.

In Vivo

Tabalumab (500 μg/rat; s.c.; single) leads to decreased B-cells and a reduction in non-canonical nF-κB signaling[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Human BAFF Tg mice[1].
Dosage:	500 μg/rat
Administration:	Subcutaneous injection, single.
Result:	Significantly decreased the splenic B-cell count between day 4 and 8. Decreased levels of p52, which returned to near the BAFF Tg level at Day 23.

REFERENCES

[1]. Manetta J, et al. Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor. J Inflamm Res. 2014 Aug 20;7:121-31.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA